Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Gene Therapy
Research findings from Ruhr University update understanding of gene therapy
March 26th, 2008
According to recent research from Bochum, Germany, "We evaluated the suitability of the Friend Virus (FV) model for the development of improved adenovirus vectors for anti-retrovirat vaccination using two types of adenovirus vectors, encoding F-MuLV Env and Gag, which differed only in their fiber genes (Ad5 and Ad5F35). Genetically FV-resistant C57BL/6 mice and highly susceptible CB6F1 hybrid mice were vaccinated by either homologous or heterologous prime-boost regimen." "After FV challenge, viral loads in the spleens of C57BL/6 mice were reduced similar to 250-fold and were below the detection threshold in > 50% of the mice. Vaccination outcome was critically...
Source: Vaccine Weekly (2008-03-26)
|
